RELATED CONTENT
The radiation therapy market, hit hard in 2009 by the recession, saw a sharp decline in purchasing from which it has slowly recovered. During the last five years the market has been steadily growing, with capital equipment budgets for radiation oncology sites increasing. However, it has only been within the last year that equipment purchases for radiation therapy have leveled out. Purchasing decisions today are driven by two main factors: advancements in technology, including more targeted treatment, multifunctional capabilities and improved patient safety; and the evolving reimbursement model, which weighs patient outcomes and the quality of care delivered more heavily.
June 03, 2014 
A clinical trial for breast cancer, published in the medical journal The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the Zeiss Intrabeam at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients.
January 09, 2014
Carl Zeiss MicroImaging Inc., a leading provider of microscopy solutions for a variety of research, clinical and industrial applications, introduces its Laser TIRF 3 microscope system, designed to enable visualization of near-cell membrane dynamic processes while maintaining optimum specimen incubation conditions.
July 08, 2009
Intrabeam is a miniature radiation source that delivers high dose, yet is a low energy X-ray used for breast cancer ...
September 22, 2008
Intrabeam is a miniature radiation source that delivers high-dose, yet is a low energy X-ray used for breast cancer ...
August 03, 2008